Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMelatonin and Wegovy are not known to interact in any clinically significant way, but the question deserves a proper answer. Semaglutide (the active ingredient in Wegovy) slows gastric emptying, which affects how quickly many substances are absorbed — and that has led some people to wonder whether melatonin supplements behave differently on treatment. The short answer is that no specific interaction has been identified, and melatonin does not appear on the list of medicines whose absorption is meaningfully disrupted by semaglutide. Even so, these are prescription-only medicines requiring individual clinical assessment, and a prescriber who knows your full picture is always the right person to ask about adding any supplement. If you are already taking Wegovy and sleeping poorly, it is worth understanding what the current evidence does (and does not) tell us, rather than reaching a conclusion from an incomplete web search.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy works by activating GLP-1 receptors in the gut and brain, reducing appetite and slowing the rate at which the stomach empties its contents into the small intestine. That gastric-emptying effect is well documented in the NHS semaglutide medicines page and is part of why the medicine produces such sustained appetite reduction. Where it becomes relevant to supplements is that anything taken by mouth passes through a stomach that is emptying more slowly than usual, which can push back the time it takes for absorption to begin.
For most supplements, this is a timing question rather than a safety question. Melatonin, taken as a sleep aid in the evening, is typically swallowed hours after any meal, and at a point when gastric-emptying effects are less pronounced than they are around food. There is no published pharmacokinetic data specifically examining melatonin absorption under semaglutide treatment, but the absence of a flagged interaction in the Wegovy prescribing information is meaningful context. The Wegovy SmPC does note that paracetamol's time to maximum concentration was delayed in one study, though the total amount absorbed was unchanged, a useful illustration of the kind of modest timing shift that can occur, rather than a genuine reduction in effect.
The practical implication: if you take melatonin at bedtime, the overlap with peak gastric-emptying activity from your weekly injection is likely to be small. That said, if you have specific health conditions alongside your weight-loss treatment, it is worth reading our detailed guidance on whether you can take melatonin with Wegovy, which looks at the question from several clinical angles. "Likely to be small" is not the same as "your prescriber has considered it", and for anyone taking multiple medicines or supplements, that personalised review matters.
It is understandable that people on Wegovy start thinking more carefully about sleep. Weight-loss treatment involves a lot of body changes at once, appetite shifts, occasional nausea in the early weeks, and sometimes disrupted routines. Poor sleep is not just uncomfortable; research consistently links inadequate rest to greater appetite, higher levels of ghrelin (a hunger hormone), and slower fat loss even when calorie intake is controlled. So the instinct to optimise sleep while on a weight-loss programme is a sensible one.
Melatonin sits in an interesting regulatory position in the UK. Low-dose melatonin supplements are sold over the counter in pharmacies; prescription-strength melatonin (Circadin, 2mg modified-release) is used for short-term insomnia management in adults over 55. The doses differ substantially, and the evidence base for the prescription form is much stronger. If sleep disruption is genuine and ongoing, it is worth raising with your GP or prescriber, not just reaching for a supplement. Our general FAQs touch on some of the lifestyle considerations that come up during treatment.
For anyone living with a neurological condition and considering semaglutide, our page covering MS and Wegovy is another example of a side-topic that gets little formal coverage but matters to real patients.
The NHS guidance on semaglutide advises patients to tell their prescriber or pharmacist about all medicines, vitamins and supplements before starting treatment. That is not a boilerplate precaution, it reflects the fact that semaglutide's gastric-emptying effect, while modest in most cases, is a real pharmacological variable. The medicines specifically studied and noted in the SmPC include oral contraceptives and paracetamol; melatonin is not among them, which tells us it was not identified as a priority concern during clinical development.
NICE's recommendation of semaglutide for weight management (covered in NICE technology appraisal TA875) focuses on BMI eligibility and the requirement for structured support rather than supplement interactions, but the broader principle that treatment works best when a clinician holds the full picture runs through all of it. If you are weighing up the cost of private treatment alongside questions like this one, the cost context for Wegovy in the UK may also be useful background.
One area where the evidence is clearer: certain oral medicines do need careful timing alongside semaglutide. Oral contraceptives in particular are flagged in NHS guidance, something discussed in more detail on pages covering B12 and Wegovy, where the broader question of nutritional absorption on treatment gets a thorough look. Sleep supplements like melatonin have a more benign profile, but if you are also noticing changes to your skin since starting treatment, our page on Wegovy and skin covers another dimension of how the body responds that patients often find worth understanding.
The evidence does not give a reason to avoid melatonin on Wegovy. What it does give is a clear process to follow. Tell whoever manages your Wegovy prescription about any supplement you are considering, including the dose and how often you plan to take it. This is especially relevant if you are also taking other medicines that could affect the central nervous system or sleep architecture, such as antihistamines or antidepressants, where the interaction picture is more complex.
If you are exploring Wegovy for the first time and wondering whether it is the right treatment for your situation, the Wegovy overview covers the full eligibility picture, how it differs from other licensed options, and what treatment involves in practice. For the broader question of which weight-loss pathway suits you, our weight-loss treatment overview sets out the options clearly.
Getting the details right from the start matters. A quick conversation with a prescriber who knows your history is worth more than any generalised guidance, and when you're trying to make sense of treatment while also not sleeping well, that honest acknowledgement feels like the least we can offer. Speak to our prescribers through a free consultation, and bring your supplement list with you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.